Is Aurinia Pharmaceuticals Inc. (AUPH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.9% / 30% | 20.9% / 30% | 2.2% / 30% | 4.8% / 5% | ✓ HALAL |
| DJIM | 3.9% / 33% | 20.9% / 33% | 2.2% / 33% | 4.8% / 5% | ✓ HALAL |
| MSCI | 10.0% / 33% | 53.0% / 33% | 5.5% / 33% | 4.8% / 5% | ✗ NOT HALAL |
| S&P | 3.9% / 33% | 20.9% / 33% | 2.2% / 33% | 4.8% / 5% | ✓ HALAL |
| FTSE | 10.0% / 33% | 53.0% / 33% | 5.5% / 50% | 4.8% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 77.0% | |
| Operating Margin | 55.7% | |
| Net Margin | 101.5% | |
| Return on Equity (ROE) | 59.9% | |
| Return on Assets (ROA) | 11.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $136M |
| Free Cash Flow | $135M |
| Total Debt | $75M |
| Debt-to-Equity | 12.9 |
| Current Ratio | 5.2 |
| Total Assets | $752M |
Price & Trading
| Last Close | $14.60 |
| 50-Day MA | $14.49 |
| 200-Day MA | $12.87 |
| Avg Volume | 980K |
| Beta | 1.6 |
|
52-Week Range
$6.83
| |
About Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Purification Calculator
As a halal stock with 4.80% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aurinia Pharmaceuticals Inc. (AUPH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aurinia Pharmaceuticals Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aurinia Pharmaceuticals Inc.'s debt ratio?
Aurinia Pharmaceuticals Inc.'s debt ratio is 3.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.0%.
Does Aurinia Pharmaceuticals Inc. require dividend purification?
Yes, Aurinia Pharmaceuticals Inc. has an impermissible income ratio of 4.80%, which means 4.80% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Aurinia Pharmaceuticals Inc.'s key financial metrics?
Aurinia Pharmaceuticals Inc. has a market capitalization of $1.9B, trailing P/E ratio of 6.9, and revenue of $283M. The company maintains a gross margin of 77.0% and a net margin of 101.5%. Return on equity stands at 59.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.